In their recent JAMA contribution, Obstacles to Developing Cost-Lowering Health Technology – The Inventor’s Dilemma”, Drs. Kellerman and Desai make a compelling case for how market forces “discourage developers from creating cost-lowering technologies, even those that might produce substantial health benefits”.

While the article focuses on medication development, the same concerns exist within the remainder of the healthcare industry.  As I read (and re-read) this article, I was struck by how the M+A advisor can impact this dilemma by furthering their own knowledge of the “clinical side” of the companies they work with and also how investors can gain excellent returns through acquiring systems that will deliver such “substantial” health related benefits. I hope you can take a look at this thought provoking piece – it was published on line on August 17, 2015 and is available at http://jama.jamanetwork.com/article.aspx?articleid=2429454  

At VERTESS we are dedicated to helping you achieve your greatest potentials and performance.  We are a nationally recognized M + A firm with a proven track record of assisting healthcare and human services providers improve their performance and, if desired, their marketability.  For additional information, please contact Glenn Lippman, MD, DFAPA, Consulting Physician/Partner at glippman@vertess.com or 602.885.2069.